TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31079849

Group type: EXPERIMENTAL
Intervention: H10N8 100-µg IM dose
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: H10N8 25-µg intradermal dose
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: H7N9 IM doses of 10 µg
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: H7N9 IM doses of 25 µg
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: H7N9 IM doses of 50 µg
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: H10N8 100 µg IM
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: H7N9 50 µg
Number of subjects: 357
Study: 30109669

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Low Calorie Diet (LCD)
Number of subjects: 86
Study: 26938706

Group type: EXPERIMENTAL
Intervention: Prediction models for disease progression
Number of subjects: 1113
Study: 24615194

Group type: EXPERIMENTAL
Intervention: Hypofractionated conformal radiotherapy (RT) combined with chemotherapy (CHT)
Number of subjects: 100
Study: 23031623

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 134
Study: 20862644

Group type: EXPERIMENTAL
Intervention: Paroxetine (dose-escalation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose of SSRIs
Number of subjects: 0
Study: 17823083

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (60 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (non-osteoporotic postmenopausal women)
Number of subjects: 22
Study: 16200917

Group type: EXPERIMENTAL
Intervention: Psychological stress control program (interview, video, informative literature, anxiety control techniques)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no psychological intervention)
Number of subjects: 74
Study: 11837381

Group type: EXPERIMENTAL
Intervention: 320 mg valsartan tablet
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2 x 160 mg valsartan capsules
Number of subjects: 40
Study: 10214735

Group type: EXPERIMENTAL
Intervention: Controlled-release physostigmine 30 mg daily
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Controlled-release physostigmine 36 mg daily
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Controlled-release physostigmine (both dosages)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study: 7609260

Group type: EXPERIMENTAL
Intervention: Escort strategy (child escorted to a nearby pediatric clinic for immunization)
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Voucher incentive strategy (family returns monthly for WIC food vouchers until child is immunized)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Referral strategy (family passively referred for immunization)
Number of subjects: 836
Study: 2649811

Group type: EXPERIMENTAL
Intervention: Yuzpe's postcoital method (0.1 mg ethinyloestradiol and 1 mg d1‐norgestrel taken within 72 hours of unprotected intercourse and repeated 12 hours later)
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Levonorgestrel pills
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Yuzpe's method taken after 48 hours
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Yuzpe's method taken before 12 hours
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Yuzpe's method (any timing)
Number of subjects: 909
Study: 367425

Group type: EXPERIMENTAL
Intervention: Methyldopa treatment for hypertension in pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treated group (methyldopa)
Number of subjects: 0
Study: 31405797

Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 403

Group type: COMPARATOR
Intervention: Black participants
Number of subjects: 403

Group type: COMPARATOR
Intervention: Hispanic participants
Number of subjects: 403
Study: 28135846

Group type: EXPERIMENTAL
Intervention: Lithium monotherapy (N=49)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Sertraline monotherapy (N=45)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lithium/Sertraline combination (N=48)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lithium/Sertraline combination
Number of subjects: 142
Study: 27557302

Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg per kilogram of body weight) in combination with bortezomib (1.3 mg per square meter) and dexamethasone (20 mg)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Bortezomib (1.3 mg per square meter) and dexamethasone (20 mg) alone
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Daratumumab group
Number of subjects: 498

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 498
Study: 24858505

Group type: EXPERIMENTAL
Intervention: Forest environment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Urban environment
Number of subjects: 36
Study: 21843878

Group type: EXPERIMENTAL
Intervention: Slope walking
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stair walking
Number of subjects: 12

Group type: COMPARATOR
Intervention: Level walking
Number of subjects: 12
Study: 19092676

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 62
Study: 17284894

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (90 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15317980

Group type: EXPERIMENTAL
Intervention: Moderate training program (n=8)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No training intervention (n=4)
Number of subjects: 12
Study: 11564000

Group type: EXPERIMENTAL
Intervention: Rebamipide 100 mg, three times a day for 8 weeks
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Rebamipide 200 mg, three times a day for 8 weeks
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Rebamipide 100 mg
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Rebamipide 200 mg
Number of subjects: 557

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study: 9577366

Group type: EXPERIMENTAL
Intervention: WHO Colour Scale
Number of subjects: 1213
Study: 8161290

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 3664914

Group type: EXPERIMENTAL
Intervention: nalbuphine 20 mg IV
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: nalbuphine 40 mg IV
Number of subjects: 150

Group type: COMPARATOR
Intervention: meperidine 75 mg IM
Number of subjects: 150
Study: 31667802

Group type: EXPERIMENTAL
Intervention: HPyV10 detected in stool specimens from children with acute diarrhoea
Number of subjects: 566

Group type: COMPARATOR
Intervention: HPyV10 detected in stool specimens from healthy asymptomatic children
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: HPyV11 detected in stool specimens from children with acute diarrhoea
Number of subjects: 566

Group type: COMPARATOR
Intervention: HPyV11 detected in stool specimens from healthy asymptomatic children
Number of subjects: 566
Study: 29471865

Group type: EXPERIMENTAL
Intervention: NECT (nifurtimox-eflornithine combination) - 200 mg/kg eflornithine infusions every 12 hours for 7 days and 8 hourly oral nifurtimox at 5 mg/kg for 10 days
Number of subjects: 109

Group type: COMPARATOR
Intervention: Eflornithine monotherapy - 100 mg/kg every 6 hours for 14 days
Number of subjects: 109
Study: 27177316

Group type: EXPERIMENTAL
Intervention: Treatment interruption
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continued ART
Number of subjects: 42
Study: 24747553

Group type: EXPERIMENTAL
Intervention: Vertical vaginal cuff closure
Number of subjects: 52

Group type: COMPARATOR
Intervention: Horizontal vaginal cuff closure
Number of subjects: 52
Study: 22404798

Group type: EXPERIMENTAL
Intervention: Thinking + Doing = Daring (TDD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study: 21189165

Group type: EXPERIMENTAL
Intervention: Pycnogenol® (Pyc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17497585

Group type: EXPERIMENTAL
Intervention: Carbohydrate (6%)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15826330

Group type: EXPERIMENTAL
Intervention: Health belief model (HBM) based intervention
Number of subjects: 833
Study: 12133045

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg
Number of subjects: 668

Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study: 8647515

Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg/day
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fluconazole 300 mg/day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Fluconazole 50 mg/day (control)
Number of subjects: 59
Study: 2213744

Group type: EXPERIMENTAL
Intervention: Stripping of the membranes
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (non-stripped group)
Number of subjects: 99
Study: 24563

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg b.i.d. (Group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg b.i.d. (Group II)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Clemastine 1 mg b.i.d. (Group III)
Number of subjects: 36
Study: 30586575

Group type: EXPERIMENTAL
Intervention: Exendin-9,39 infusion at 300 pmol/kg/min for 6 h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study: 28779304

Group type: EXPERIMENTAL
Intervention: Peloid therapy (10 sessions over 2 weeks, 5 sessions a week)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Home exercise program (control group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Peloid therapy vs Control group
Number of subjects: 63
Study: 27670399

Group type: EXPERIMENTAL
Intervention: Weight management intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 114
Study: 23711809

Group type: EXPERIMENTAL
Intervention: Intrathrombus urokinase (200,000 U)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 102
Study: 21854611

Group type: EXPERIMENTAL
Intervention: Health risk factors (smoking, risky drinking, overweight/obesity, etc.)
Number of subjects: 7906

Group type: EXPERIMENTAL
Intervention: Health risk factors (substance use, nutrition, physical inactivity)
Number of subjects: 7906

Group type: EXPERIMENTAL
Intervention: Health risk factors (various)
Number of subjects: 7906
Study: 19647409

Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Real-Time Three-Dimensional Echocardiography (RT3DE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TDI
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: RT3DE
Number of subjects: 90
Study: 17919093

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy, counseling, and self-help written materials
Number of subjects: 95
Study: 14758135

Group type: EXPERIMENTAL
Intervention: 5 years of tamoxifen after CNF chemotherapy and ovarian ablation (Group B)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: 6 cycles of CNF followed by 5 years of tamoxifen (Group D)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: 5 years of tamoxifen (Group C)
Number of subjects: 456

Group type: COMPARATOR
Intervention: CNF chemotherapy
Number of subjects: 456
Study: 11708731

Group type: EXPERIMENTAL
Intervention: Virtual reality treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cognitive-behavioral psychonutritional groups
Number of subjects: 28
Study: 9812083

Group type: EXPERIMENTAL
Intervention: Bedside monitoring
Number of subjects: 1713

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 1713
Study: 7928850

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg of Zn and 1.5 mg of copper)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 2789542

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Alpha-methyldopa
Number of subjects: 26
Study: 1092511

Group type: EXPERIMENTAL
Intervention: Amitriptyline in combination with alcohol (0.5 gm/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Doxepin in combination with alcohol (0.5 gm/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amitriptyline and Doxepin in combination with alcohol (0.5 gm/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nortriptyline and Chlorimipramine
Number of subjects: 40
Study: 31119849

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 77
Study: 30885158

Group type: EXPERIMENTAL
Intervention: Intervention group (33 villages)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (33 villages)
Number of subjects: 66
Study: 28637922

Group type: EXPERIMENTAL
Intervention: Lampalizumab administered by intravitreal injection monthly
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Lampalizumab administered by intravitreal injection every other month
Number of subjects: 123

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Lampalizumab (monthly) in CFI risk-allele carriers
Number of subjects: 123
Study: 24824415

Group type: EXPERIMENTAL
Intervention: World Health Organization Surgical Safety Checklist (SSC)
Number of subjects: 4475

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4475
Study: 22612171

Group type: EXPERIMENTAL
Intervention: Concurrent motor tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent verbal tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent visual tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manipulable objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmanipulable objects
Number of subjects: 0
Study: 21310287

Group type: EXPERIMENTAL
Intervention: PATH Woman's Condom
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: FC2
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: V‐Amour
Number of subjects: 170

Group type: COMPARATOR
Intervention: All condom types
Number of subjects: 170
Study: 20134218

Group type: EXPERIMENTAL
Intervention: Exercise program below 90 degrees
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise program above 90 degrees
Number of subjects: 30
Study: 16923101

Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 80 mg parecoxib
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 73
Study: 15758246

Group type: EXPERIMENTAL
Intervention: Nateglinide (90 mg)
Number of subjects: 36
Study: 11423492

Group type: EXPERIMENTAL
Intervention: Low glycemic index dietary advice
Number of subjects: 104

Group type: COMPARATOR
Intervention: Measured carbohydrate exchange diet (CHOx)
Number of subjects: 104
Study: 9390981

Group type: EXPERIMENTAL
Intervention: High-dose creatine intake (20 g/day) for 4 days followed by low-dose creatine intake (5 g/day) during 10 weeks of training
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low-dose creatine intake (5 g/day) during 10 weeks of training
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low-dose creatine intake (5 g/day) during 10 weeks of detraining
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cessation of creatine intake
Number of subjects: 19
Study: 7517058

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU upon anesthetic induction, similar dose in the priming pump, maintenance dose of 500,000 KIU/h)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups (no significant difference)
Number of subjects: 102
Study: 3294015

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 62
Study: 31251716

Group type: EXPERIMENTAL
Intervention: Burch procedure
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sling procedure
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 29
Study: 28277865

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 376

Group type: COMPARATOR
Intervention: Agomelatine
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Remitters (n=142)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Nonremitters (n=233)
Number of subjects: 376
Study: 25553506

Group type: EXPERIMENTAL
Intervention: Etomidate-remifentanil
Number of subjects: 720

Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 720
Study: 22527327

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections (mean number of 5.0 injections) in patients with SMD
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections (mean number of 4.3 injections) in patients without SMD
Number of subjects: 49
Study: 20862628

Group type: EXPERIMENTAL
Intervention: Standardized nutritional regimen (ST-Group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Individual nutritional regimen (IN-Group)
Number of subjects: 99
Study: 18482144

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study: 16489473

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 14629706

Group type: EXPERIMENTAL
Intervention: Individualized dose regimen of amitriptyline (n = 30) for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Empiric dose regimen of amitriptyline (n = 30) for 8 weeks
Number of subjects: 60
Study: 11268416

Group type: EXPERIMENTAL
Intervention: Single training trial with olfactory cue and allergen challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three training trials with olfactory cue and allergen challenge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single training trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second test trial
Number of subjects: 0
Study: 9010373

Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 85

Group type: COMPARATOR
Intervention: No block
Number of subjects: 85
Study: 8093291

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60 mg retinol equivalent)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 2436856

Group type: EXPERIMENTAL
Intervention: Ringer's acetate‐gluconate solution (56 +/- 15 ml/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 6% dextran‐70 (16 +/- 6 ml/kg)
Number of subjects: 32
Study: 31069459

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g/day from 24 weeks of gestation until delivery)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional yoghurt
Number of subjects: 130
Study: 28741134

Group type: EXPERIMENTAL
Intervention: Feeding Buddies programme
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Training and community caregiver visit
Number of subjects: 625
Study: 27346784

Group type: EXPERIMENTAL
Intervention: Activated photochromic lenses (Gray1, Gray2, Brown)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Activated photochromic lenses (Gray1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Clear polycarbonate lens (control)
Number of subjects: 75
Study: 25683276

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Transient anemia
Number of subjects: 18113
Study: 23780564

Group type: EXPERIMENTAL
Intervention: Octreotide 25 ug h(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Octreotide 50 ug h(‐1)
Number of subjects: 0
Study: 21194827

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Hyoscine (10 mg)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 18492548

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 107

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 107
Study: 16446007

Group type: EXPERIMENTAL
Intervention: Propionyl l-carnitine (PLC) 2 g/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 12522753

Group type: EXPERIMENTAL
Intervention: Investigational antiretroviral agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 0
Study: 10813126

Group type: EXPERIMENTAL
Intervention: Micronized purified flavonidic fraction plus ispaghula husk
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Rubber band ligation plus ispaghula husk
Number of subjects: 162

Group type: COMPARATOR
Intervention: Ispaghula husk alone
Number of subjects: 162
Study: 8969979

Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study: 1589923

Group type: EXPERIMENTAL
Intervention: MFR-guided dilatation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional scale dilatation (Control)
Number of subjects: 70
Study: 6388247

Group type: EXPERIMENTAL
Intervention: 100 mg moclobemide
Number of subjects: 38

Group type: COMPARATOR
Intervention: 50 mg clomipramine
Number of subjects: 38
Study: 31660240

Group type: EXPERIMENTAL
Intervention: Hybrid mentor training approach (90-minute self-paced online module + workshops)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control condition (two-page mentoring tip sheet)
Number of subjects: 59
Study: 29265404

Group type: EXPERIMENTAL
Intervention: Invagination pancreaticojejunostomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Duct-to-mucosa pancreaticojejunostomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Invagination pancreaticojejunostomy (in soft pancreas subgroup)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Duct-to-mucosa pancreaticojejunostomy (in soft pancreas subgroup)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Invagination pancreaticojejunostomy (among patients with clinically relevant POPF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Duct-to-mucosa pancreaticojejunostomy (among patients with clinically relevant POPF)
Number of subjects: 120
Study: 26659199

Group type: EXPERIMENTAL
Intervention: 0.2 mA
Number of subjects: 94

Group type: COMPARATOR
Intervention: 0.5 mA
Number of subjects: 94